CINGW

Insider Trades

Name	Value	Action	Price	Last Price
Werth Peter J.Director $98k19.5k shares BuyFeb 6, 2026 $5.04 $0.0218
Werth Peter J.Director $78k15.6k shares BuyFeb 6, 2026 $5.04 $0.0218
Schaffer Shane J.Director, Officer: Chief Executive Officer $34k6.8k shares BuyFeb 6, 2026 $5.04 $0.0218
Schaffer Shane J.Director, Officer: Chief Executive Officer $27k5.4k shares BuyFeb 6, 2026 $5.04 $0.0218
Callahan Jennifer L.SVP And CFO $25k4.9k shares BuyFeb 6, 2026 $5.04 $0.0218
Callahan Jennifer L.SVP And CFO $20k3.9k shares BuyFeb 6, 2026 $5.04 $0.0218

Trade CINGW

About Cingulate Inc.

Cingulate Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to pioneering therapies for central nervous system and neurobiological conditions. Its leading investigational medicines are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both designed to manage attention deficit/hyperactivity disorders (ADHD). Furthermore, the company is progressing CTx-2103 for the treatment of anxiety disorders. Established in 2012, Cingulate Inc. maintains its main office in Kansas City, Kansas, and also operates a facility in Morristown, New Jersey.

CEO: Shane J. Schaffer
IPO Date: Dec 8, 2021

Market Data

Open: $0.0385
High: $0.0385
Low: $0.0279
Volume: 1K
52W High: $0.0385
52W Low: $0.0279

Valuation

Market Cap: $188.4K
Enterprise Value: $8.9M

Financials

Free Cash Flow: -$17.4M
Revenue: $0
Net Income: -$22.4M
Cash: $11M
Debt: $8.8M

Events

EarningsAug 18

EPS est. -0.625